Market Research Life Sciences Market Research Pharmaceuticals Market Research Therapeutic Area Market Research CNS/Neurology Market Research

Dementia and Alzheimer’s Disease Treatment Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028

Best Price Guarantee Length Publisher Published Date SKU
from $4,900 112 Pages TechSci Research December, 2022 TCSI17563438
Best Price Guarantee
Price from $4,900
Length 112 Pages
Publisher TechSci Research
Published Date December, 2022
SKU TCSI17563438

Dementia and Alzheimer’s Disease Treatment Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028

Global dementia and Alzheimer’s disease treatment market is expected to grow at impressive growth during the forecast period, 2024-2028. The increasing cases of Alzheimer's and dementia coupled with growing awareness regarding the diseases are bolstering the growth of the market. Moreover, elderly population are more prone to such diseases due to growing age, which in turn, is expected to positively impact the growth of market. Also, upsurge in R&D activities associated with disease, the introduction of new and innovative technologies and drugs, and increasing government initiatives such as investments, awareness programmes are expected to bolster the growth of market over the next few years. For instance, in 2022, a new initiative by McGill University’s Dementia Education Program received funding from the Public Health Agency of Canada to raise awareness of dementia and promote dementia-inclusive communities.

The global dementia and Alzheimer’s disease treatment market is segmented into drug class, distribution channel, company and region. Based on drug class, the market is categorized into cholinergic/cholinesterase (ChE) inhibitors, memantine, and combination drugs. Out of these, the cholinergic/cholinesterase (ChE) inhibitor segment dominates the dementia and Alzheimer’s disease market. This is accredited to fact that it is first line of treatment for AD and most widely prescribed drug for the treatment. In addition, the drug is very effective for treating mild to severe dementia, which is contributing to the increasing growth of the segment.

The memantine segment is further expected to be the fastest growing segment during the forecast period. This is ascribed to its suitability in cholinergic/cholinesterase inhibitors intolerant patients suffering from AD.

Major players operating in the global dementia and Alzheimer’s disease treatment market include Merz Pharma GmbH & Co. KGaA, Novartis AG, Pfizer, Inc., Ono Pharmaceutical Co., Ltd., Johnson & Johnson Services, Inc., H. Lundbeck A/S, F. Hoffmann-La Roche Ltd., AbbVie Inc., Eli Lilly and Company, and Corium, Inc. The companies are adopting new strategies in order to stay competitive in the market. Rising competitiveness is anticipated to drive innovation in the market, thereby helping the industry to solve existing challenges and meet the needs of the market.

Objective of the Study:

  • To analyze and estimate the market size of global dementia and Alzheimer’s disease treatment market from 2018 to 2021.
  • To estimate and forecast the market size of global dementia and Alzheimer’s disease treatment market from 2022 to 2028 and growth rate until 2028.
  • To classify and forecast global dementia and Alzheimer’s disease treatment market based on drug class, distribution channel, company and regional distribution.
  • To identify dominant region or segment in the global dementia and Alzheimer’s disease treatment market.
  • To identify drivers and challenges for global dementia and Alzheimer’s disease treatment market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global dementia and Alzheimer’s disease treatment market.
  • To conduct pricing analysis for global dementia and Alzheimer’s disease treatment market.
  • To identify and analyze the profile of leading players operating in global dementia and Alzheimer’s disease treatment market.
  • to identify key sustainable strategies adopted by market players in global dementia and Alzheimer’s disease treatment market.
TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of companies across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the hospitals and presence of all major players across the globe.

TechSci Research calculated the market size of global dementia and Alzheimer’s disease treatment market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:
  • Dementia and Alzheimer’s disease treatment facilities and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to dementia and Alzheimer’s disease treatment
  • Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as companies, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global dementia and Alzheimer’s disease treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
  • Global Dementia and Alzheimer’s Disease Treatment Market, By Drug Class:
  • Cholinergic/ Cholinesterase Inhibitors
  • Donepezil
  • Galantamine
  • Rivastigmine
  • Memantine
  • Combination Drugs
  • Memantine
  • Donepezil
  • Global Dementia and Alzheimer’s Disease Treatment Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Dementia and Alzheimer’s Disease Treatment Market, By Region:
  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • South America
  • Brazil
  • Argentina
  • Colombia
Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global dementia and Alzheimer’s disease treatment market.

Company Information
  • Detailed analysis and profiling of additional market players (up to five).
Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.


1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Clinical Trial Analysis
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Type
5.7. Breakdown of Pipeline, By Country
5.8. Clinical Trials Heat Map
6. Global Dementia and Alzheimer’s Disease Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class (Cholinergic/ Cholinesterase (ChE) Inhibitors [Donepezil, Galantamine, Rivastigmine], Memantine, Combination Drugs [Memantine & Donepezil]
6.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies)
6.2.3. By Company (2022)
6.2.4. By Region
6.3. Market Attractiveness Index
7. Asia-Pacific Dementia and Alzheimer’s Disease Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Distribution Channel
7.2.3. By Country
7.3. Asia-Pacific: Country Analysis
7.3.1. China Dementia and Alzheimer’s Disease Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Distribution Channel
7.3.2. India Dementia and Alzheimer’s Disease Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Distribution Channel
7.3.3. Australia Dementia and Alzheimer’s Disease Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Distribution Channel
7.3.4. Japan Dementia and Alzheimer’s Disease Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Class
7.3.4.2.2. By Distribution Channel
7.3.5. South Korea Dementia and Alzheimer’s Disease Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Class
7.3.5.2.2. By Distribution Channel
8. Europe Dementia and Alzheimer’s Disease Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Distribution Channel
8.2.3. By Country
8.3. Europe: Country Analysis
8.3.1. France Dementia and Alzheimer’s Disease Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Distribution Channel
8.3.2. Germany Dementia and Alzheimer’s Disease Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Distribution Channel
8.3.3. United Kingdom Dementia and Alzheimer’s Disease Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Distribution Channel
8.3.4. Italy Dementia and Alzheimer’s Disease Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Distribution Channel
8.3.5. Spain Dementia and Alzheimer’s Disease Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Distribution Channel
9. North America Dementia and Alzheimer’s Disease Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Distribution Channel
9.2.3. By Country
9.3. North America: Country Analysis
9.3.1. United States Dementia and Alzheimer’s Disease Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Distribution Channel
9.3.2. Mexico Dementia and Alzheimer’s Disease Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Distribution Channel
9.3.3. Canada Dementia and Alzheimer’s Disease Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Distribution Channel
10. South America Dementia and Alzheimer’s Disease Treatment Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Class
10.2.2. By Distribution Channel
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Dementia and Alzheimer’s Disease Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Class
10.3.1.2.2. By Distribution Channel
10.3.2. Argentina Dementia and Alzheimer’s Disease Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Class
10.3.2.2.2. By Distribution Channel
10.3.3. Colombia Dementia and Alzheimer’s Disease Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Class
10.3.3.2.2. By Distribution Channel
11. Middle East and Africa Dementia and Alzheimer’s Disease Treatment Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Drug Class
11.2.2. By Distribution Channel
11.2.3. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Dementia and Alzheimer’s Disease Treatment Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Drug Class
11.3.1.2.2. By Distribution Channel
11.3.2. Saudi Arabia Dementia and Alzheimer’s Disease Treatment Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Drug Class
11.3.2.2.2. By Distribution Channel
11.3.3. UAE Dementia and Alzheimer’s Disease Treatment Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Drug Class
11.3.3.2.2. By Distribution Channel
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
14. Competitive Landscape
14.1. Merz Pharma GmbH & Co. KGaA
14.2. Novartis AG
14.3. Pfizer, Inc.
14.4. Ono Pharmaceutical Co., Ltd.
14.5. Johnson & Johnson Services, Inc.
14.6. H. Lundbeck A/S
14.7. F. Hoffmann-La Roche Ltd.
14.8. AbbVie Inc.
14.9. Eli Lilly and Company
14.10. Corium, Inc.
15. Strategic Recommendations

$4,900
$5,900
$8,900

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings